These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30718561)

  • 1. Diagnostic Value of Circulating microRNAs for In-Stent Restenosis in Patients with Lower Extremity Arterial Occlusive Disease.
    Yuan L; Dong J; Zhu G; Bao J; Lu Q; Zhou J; Jing Z
    Sci Rep; 2019 Feb; 9(1):1402. PubMed ID: 30718561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of microRNA-143 in predicting in-stent restenosis for patients with lower extremity arterial occlusive disease.
    Yu ZH; Wang HT; Tu C
    Eur J Med Res; 2017 Jan; 22(1):2. PubMed ID: 28057086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating mircoRNA-21 as a predictor for vascular restenosis after interventional therapy in patients with lower extremity arterial occlusive disease.
    Zhang B; Yao Y; Sun QF; Liu SQ; Jing B; Yuan C; Liu XY; Jiao T; Li HC; Wang HY
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28250135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case-control study.
    Pan CH; Chien SC; Chen CJ; Shih CM; Hsieh MH; Huang CY; Bi WF; Chan CS; Kao YT; Hsiao CY; Chiang SJ; Chiang KH; Huang JH; Liu YR; Luo JD; Huang HY; Wu CH
    BMC Cardiovasc Disord; 2021 Feb; 21(1):77. PubMed ID: 33557763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
    Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miRNA-23b and miRNA-143 Are Potential Biomarkers for In-Stent Restenosis.
    Saavedra N; Rojas G; Herrera J; Rebolledo C; Ruedlinger J; Bustos L; Bobadilla B; Pérez L; Saavedra K; Zambrano T; Lanas F; Salazar LA
    Biomed Res Int; 2020; 2020():2509039. PubMed ID: 33015157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention.
    Dai R; Liu Y; Zhou Y; Xiong X; Zhou W; Li W; Zhou W; Chen M
    J Clin Lab Anal; 2020 Jan; 34(1):e23013. PubMed ID: 31495986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis.
    He M; Gong Y; Shi J; Pan Z; Zou H; Sun D; Tu X; Tan X; Li J; Li W; Liu B; Xue J; Sheng L; Xiu C; Yang N; Xue H; Ding X; Yu C; Li Y
    PLoS One; 2014; 9(11):e112043. PubMed ID: 25427155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease.
    Kurtul A; Murat SN; Yarlioglues M; Duran M; Karadeniz M; Ergun G; Akyel A; Mendi MA; Oksuz F
    Platelets; 2015; 26(1):48-52. PubMed ID: 24831828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease.
    Zhu ZR; He Q; Wu WB; Chang GQ; Yao C; Zhao Y; Wang M; Wang SM
    J Atheroscler Thromb; 2018 Nov; 25(11):1168-1181. PubMed ID: 29760303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention].
    Guan JJ; Zhang Y; Liu YJ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr; 34(4):304-308 384. PubMed ID: 30788936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNA-21 as Stable Blood-Based Markers for Patients With ISR After PCI.
    Zhang X; Xiao XP; Ren XA; Xue W
    Heart Surg Forum; 2020 Oct; 23(6):E756-E762. PubMed ID: 33234202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients.
    Li H; Gui H; Yuan G; Zheng X; Gao C; Yuan H
    Scand J Clin Lab Invest; 2018 Jul; 78(4):269-274. PubMed ID: 29553861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
    Ganesh SK; Skelding KA; Mehta L; O'Neill K; Joo J; Zheng G; Goldstein J; Simari R; Billings E; Geller NL; Holmes D; O'Neill WW; Nabel EG
    Pharmacogenomics; 2004 Oct; 5(7):952-1004. PubMed ID: 15469413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnostic Value of Circulating Biomarkers and Role of Drug-Coated Balloons for In-Stent Restenosis in Patients with Peripheral Arterial Disease.
    Montelione N; Catanese V; Nenna A; Jawabra M; Verghi E; Loreni F; Nappi F; Lusini M; Mastroianni C; Jiritano F; Serraino GF; Mastroroberto P; Codispoti FA; Chello M; Spinelli F; Stilo F
    Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.
    Bliden KP; Tantry US; Gesheff MG; Franzese CJ; Pandya S; Toth PP; Mathew DP; Chaudhary R; Gurbel PA
    J Interv Cardiol; 2016 Apr; 29(2):168-78. PubMed ID: 26822493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leihong granule intervened in-stent restenosis after endovascular therapy for lower extremity arterial occlusive diseases: a clinical observation].
    Han B; Ge CQ; Wang LP; Zhang SF; Li HZ; Zhang HG; Zhou CG; Ji GH; Yang Z; Zhang L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):153-6. PubMed ID: 24672937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.